Hale Building for Transformative Medicine, 60 Fenwood Road, Boston, MA
The goal of Dr. Ganqiang Liu’s research is to investigate how the genome functions in the human brain and build a future precision medicine for neurodegenerative disease. His current research focuses on genetic variants and prognosis of Parkinson’s disease.
Dr. Liu found that mutations in the Beta-glucocerebrosidase gene (GBA) are causal for neuropathic Gaucher’s disease (GD) in homozygotes, and are associated with aggressive cognitive decline in heterozygous PD patients. He also developed a clinical-genetic cognitive risk score (termed CRS) to predict global cognitive impairment in patients with Parkinson’s disease. He is now leading a project focused on genetic architecture controlling PD phenotypes: discovery of novel genetic variants to predict prognosis in Parkinson’s disease at genome-wide scale using large longitudinal cohorts.
Dr. Liu received a PhD degree in Bioinformatics from the University of Queensland, Australia, training with Professor John Mattick (who pioneered the concept of non-coding or “dark matter” RNAs) at the Institute for Molecular Bioscience and at the Garvan Institute of Medical Research, and was a Research Fellow in Dr. Scherzer’s Neurogenomics Laboratory. Dr. Liu is an Instructor in Neurology at Harvard Medical School and a research assistant in Neurology of Ann Romney Center for Neurological Disease in Brigham and Women’s Hospital.